Lipocine (LPCN)
Develops oral therapies and licenses approved testosterone product TLANDO to commercialization partners.
Something off on this page? Send us feedback.
Develops oral drug formulations and earns approved-product economics through licenses, supply, and distribution arrangements, with TLANDO providing its approved testosterone therapy. The single-segment business depends on partners for commercial execution while it advances a broader therapeutic pipeline.
Develops lipid-based oral formulations that aim to make established or biologically validated active ingredients available as patient-friendly therapies. The company commercializes approved testosterone therapy TLANDO through licensing and related supply or distribution arrangements rather than a broad direct-sales infrastructure.
Its development portfolio spans postpartum depression, major depressive disorder, epilepsy, essential tremor, liver cirrhosis, obesity management, and prevention of preterm birth. This creates exposure to neuropsychiatric, endocrine and metabolic, liver-disease, and women’s-health markets while oral delivery remains the operating focus.
TLANDO’s U.S. commercial execution depends on Verity Pharma; other territories rely on separate arrangements, and candidates require clinical, regulatory, manufacturing, vendor, partner, and financing support. The company operates as a single biopharmaceutical development and licensing business.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $23.3M · Total debt $0 · Total assets $23.8M · Shareholders' equity $21.8M
- Revenue
- $190.1K
- Operating income
- −$2.8M
- Net income
- −$2.6M
No dividends on record.
| Institutions46 holders · as of Mar 31, 2026 | 37.83% | 3.12M shares | |
| Insiders2 holders · as of Apr 7, 2026 | 4.42% | 364.5K shares | |
| Otherremainder | 57.75% | 4.76M shares |
8.24M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ikarian Capital, LLCInstitution | 6.17% | 508,556 | 13Fas of Mar 31, 2026 |
Squadron Capital Management LLCInstitution | 5.46% | 450,000 | 13Fas of Mar 31, 2026 |
Squadron Master Fund LPInstitution | 5.46% | 450,000 | 13Gfiled May 15, 2026 ↗ |
Eversept Partners, LPInstitution | 3.58% | 294,989 | 13Fas of Mar 31, 2026 |
Rosalind Advisors, Inc.Institution | 2.69% | 221,616 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 7, 2026 | John W. Higuchi | director | +40,000 | $2.03 |
| Apr 6, 2026 | Mahesh V. Patel | director, officer: Chief Executive Officer | +25,000 | $2.03 |
| Apr 6, 2026 | John W. Higuchi | director | +123,000 | $2.05 |
| Apr 2, 2026 | Mahesh V. Patel | director, officer: Chief Executive Officer | +25,000 | $2.02 |
- Biogen
Approved oral therapy in postpartum depression.
- Halozyme Therapeutics
Marketed injectable testosterone alternative for hypogonadism.
- Pfizer
Injectable testosterone replacement for the same adult patients.
- Teva (ADR)
Generic topical testosterone competes for treated hypogonadism patients.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lipocine | $2.39 | +3.91% | $19.4M | — | — | 12.4 | −69.5% |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Halozyme Therapeutics | $109.66 | +0.06% | $13.01B | 32.7 | 11.5 | 7.8 | +47.7% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Teva (ADR) | $37.45 | −0.05% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Median | 38.9 | 12.4 | 3.0 | +3.0% |